| Name | Title | Contact Details |
|---|
SWORD Health is the world`s fastest growing virtual musculoskeletal (MSK) care provider, on a mission to free two billion people from chronic and post-surgical pain. The company`s clinical-grade virtual therapy platform pairs expert physical therapists with FDA-listed wearable technology to deliver a personalized treatment plan that is more effective, easier and less expensive than traditional physical therapy. SWORD Health believes in the power of people to recover at home, without resorting to imaging, surgeries or opioids. Since launching in 2015, SWORD Health has worked with insurers, health systems and employers in the U.S, Europe and Australia to make quality physical therapy more accessible to everyone. SWORD Health has offices in New York City, Chicago, Salt Lake City, Sydney and Porto.
Access Managed Healthcare is a Floral Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Swift Medical is the world leader in digital wound care management, delivering advanced wound care visualization and touchless 3D measurement through its smartphone-ready Swift Skin and Wound software. Swift`s enterprise-grade solution streamlines clinical and administrative wound care management workflows, from image capture and automatic risk scoring to assessment scheduling and claims submission. Today, Skin and Wound has been adopted by more than 4,000 facilities to monitor over 100,000 beds.
Winter Park Health Foundation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Winter Park, FL. To find more information about Winter Park Health Foundation, please visit www.wphf.org
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.